TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET 48
1.4 LIMITATIONS 51
1.5 MARKETS COVERED 51
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 CURRENCY AND PRICING 56
2.5 DBMR TRIPOD DATA VALIDATION MODEL 57
2.6 MULTIVARIATE MODELLING 60
2.7 PRODUCT TYPE LIFELINE CURVE 60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
2.9 DBMR MARKET POSITION GRID 62
2.10 VENDOR SHARE ANALYSIS 63
2.11 MARKET END COVERAGE GRID 64
2.12 SECONDARY SOURCES 65
2.13 ASSUMPTIONS 65
3 EXECUTIVE SUMMARY 66
4 PREMIUM INSIGHT 70
4.1 PESTEL'S MODEL 72
4.2 PORTER'S 5 FORCES 73
4.3 EPIDEMIOLOGY 74
4.4 BRAND ANALYSIS 75
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET 79
4.6 INDUSTRY INSIGHTS: 81
5 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY 82
5.1 NORTH AMERICA 82
5.1.1 REGULATORY SCENARIO IN THE U.S 82
5.2 EUROPEAN UNION (EU)- 83
5.3 ASIA-PACIFIC 83
5.3.1 REGULATORY SCENARIO IN AUSTRALIA- 83
5.3.2 REGULATORY SCENARIO IN JAPAN 83
5.3.3 REGULATORY SCENARIO IN CHINA 83
5.3.4 REGULATORY SCENARIO IN SINGAPORE- 84
6 MARKET OVERVIEW 86
6.1 DRIVERS 88
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA 88
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 88
6.1.3 INCREASE IN THE GERIATRIC POPULATION 89
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS 89
6.2 RESTRAINTS 90
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST 90
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES 90
6.3 OPPORTUNITIES 91
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS 91
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS 91
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS 92
6.4 CHALLENGES 93
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES 93
6.4.2 LIMITATIONS OF RADIATION TESTS 93
7 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 94
7.1 OVERVIEW 95
7.2 REAGENTS & CONSUMABLES 98
7.2.1 KITS 99
7.2.1.1 DNA POLYMERASE KITS 99
7.2.1.2 PCR KITS 99
7.2.1.3 NUCLEIC ACID ISOLATION KITS 99
7.2.1.4 OTHERS 99
7.2.2 REAGENTS 100
7.2.2.1 ASSAYS 100
7.2.2.2 BUFFERS 100
7.2.2.3 PRIMERS 100
7.2.2.4 OTHERS 100
7.3 INSTRUMENTS 101
7.4 SERVICES 102
8 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 103
8.1 OVERVIEW 104
8.2 CONFIRMATORY TEST 107
8.2.1 IMAGING TESTS 108
8.2.1.1 PET SCAN/CT SCAN 108
8.2.1.2 CT SCAN 108
8.2.1.3 ULTRASOUND 108
8.2.1.4 MRI 109
8.2.1.5 X-RAY 109
8.2.2 BIOMARKER 109
8.2.2.1 DNA BIOMARKER 109
8.2.2.2 RNA BIOMARKER 109
8.2.2.3 PROTEIN BIOMARKER 109
8.2.3 BIOPSY 109
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM 110
9 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP 111
9.1 OVERVIEW 112
9.2 GERIATRICS 115
9.3 ADULT 116
9.4 PEDIATRIC 117
10 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE 118
10.1 OVERVIEW 119
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA 122
10.3 CARCINOID TUMOR 123
10.4 GASTROINTESTINAL STROMAL TUMOR 124
10.5 GASTRIC LYMPHOMA 125
10.6 OTHERS 126
11 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE 127
11.1 OVERVIEW 128
11.2 STAGE I 131
11.2.1 STAGE IA 132
11.2.2 STAGE IB 132
11.3 STAGE II 132
11.3.1 STAGE IIA 133
11.3.2 STAGE IIB 133
11.4 STAGE III 133
11.4.1 STAGE IIIA 134
11.4.2 STAGE IIIB 135
11.4.3 STAGE IIIC 135
11.5 STAGE 0 135
12 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER 136
12.1 OVERVIEW 137
12.2 MALE 140
12.3 FEMALE 141
13 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE 142
13.1 OVERVIEW 143
13.2 STOOL 146
13.3 TISSUE 147
13.4 BLOOD 148
13.5 URINE 149
14 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER 150
14.1 OVERVIEW 151
14.2 HOSPITALS 154
14.3 DIAGNOSTIC LABORATORIES 155
14.4 CANCER RESEARCH INSTITUTES 156
14.5 ONCOLOGY SPECIALTY CLINICS 157
14.6 OTHERS 158
15 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 159
15.1 OVERVIEW 160
15.2 DIRECT TENDERS 163
15.3 RETAIL SALES 164
16 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION 165
16.1 OVERVIEW 166
16.2 NORTH AMERICA 172
16.2.1 U.S. 182
16.2.2 CANADA 187
16.2.3 MEXICO 192
16.3 EUROPE 197
16.3.1 GERMANY 208
16.3.2 FRANCE 213
16.3.3 U.K 218
16.3.4 RUSSIA 223
16.3.5 ITALY 228
16.3.6 SPAIN 233
16.3.7 BELGIUM 238
16.3.8 NETHERLANDS 243
16.3.9 TURKEY 248
16.3.10 SWITZERLAND 253
16.3.11 REST OF EUROPE 258
16.4 ASIA-PACIFIC 259
16.4.1 SOUTH KOREA 269
16.4.2 JAPAN 274
16.4.3 CHINA 279
16.4.4 AUSTRALIA 284
16.4.5 SINGAPORE 289
16.4.6 INDIA 294
16.4.7 THAILAND 299
16.4.8 MALAYSIA 304
16.4.9 INDONESIA 309
16.4.10 PHILIPPINES 314
16.4.11 REST OF ASIA-PACIFIC 319
16.5 SOUTH AMERICA 320
16.5.1 BRAZIL 330
16.5.2 ARGENTINA 335
16.5.3 REST OF SOUTH AMERICA 340
16.6 MIDDLE EAST AND AFRICA 341
16.6.1 SOUTH AFRICA 351
16.6.2 SAUDI ARABIA 356
16.6.3 U.A.E 361
16.6.4 EGYPT 366
16.6.5 ISRAEL 371
16.6.6 REST OF MIDDLE EAST AND AFRICA 376
17 GLOBAL GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 377
17.1 COMPANY SHARE ANALYSIS: GLOBAL 377
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 378
17.3 COMPANY SHARE ANALYSIS: EUROPE 379
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 380
18 SWOT ANALYSIS 381
19 COMPANY PROFILE 382
19.1 F. HOFFMANN-LA ROCHE LTD 382
19.1.1 COMPANY SNAPSHOT 382
19.1.2 REVENUE ANALYSIS 382
19.1.3 COMPANY SHARE ANALYSIS 383
19.1.4 PRODUCT PORTFOLIO 383
19.1.5 RECENT DEVELOPMENT 383
19.2 GENERAL ELECTRIC 384
19.2.1 COMPANY SNAPSHOT 384
19.2.2 REVENUE ANALYSIS 384
19.2.3 COMPANY SHARE ANALYSIS 385
19.2.4 PRODUCT PORTFOLIO 385
19.2.5 RECENT DEVELOPMENT 385
19.3 ABBOTT 386
19.3.1 COMPANY SNAPSHOT 386
19.3.2 REVENUE ANALYSIS 386
19.3.3 COMPANY SHARE ANALYSIS 387
19.3.4 PRODUCT PORTFOLIO 387
19.3.5 RECENT DEVELOPMENT 387
19.4 QIAGEN 388
19.4.1 COMPANY SNAPSHOT 388
19.4.2 REVENUE ANALYSIS 388
19.4.3 COMPANY SHARE ANALYSIS 389
19.4.4 PRODUCT PORTFOLIO 389
19.4.5 RECENT DEVELOPMENT 389
19.5 MYRIAD GENETICS, INC. 390
19.5.1 COMPANY SNAPSHOT 390
19.5.2 REVENUE ANALYSIS 390
19.5.3 COMPANY SHARE ANALYSIS 391
19.5.4 PRODUCT PORTFOLIO 391
19.5.5 RECENT DEVELOPMENT 391
19.6 ACON LABORATORIES, INC. 392
19.6.1 COMPANY SNAPSHOT 392
19.6.2 PRODUCT PORTFOLIO 392
19.6.3 RECENT DEVELOPMENT 392
19.7 ADVACARE PHARMA 393
19.7.1 COMPANY SNAPSHOT 393
19.7.2 PRODUCT PORTFOLIO 393
19.7.3 RECENT DEVELOPMENT 393
19.8 AGILENT TECHNOLOGIES, INC. 394
19.8.1 COMPANY SNAPSHOT 394
19.8.2 REVENUE ANALYSIS 394
19.8.3 PRODUCT PORTFOLIO 395
19.8.4 RECENT DEVELOPMENTS 395
19.9 BIOMRIEUX 396
19.9.1 COMPANY SNAPSHOT 396
19.9.2 REVENUE ANALYSIS 396
19.9.3 PRODUCT PORTFOLIO 397
19.9.4 RECENT DEVELOPMENT 397
19.10 BIOCEPT, INC. 398
19.10.1 COMPANY SNAPSHOT 398
19.10.2 REVENUE ANALYSIS 398
19.10.3 PRODUCT PORTFOLIO 399
19.10.4 RECENT DEVELOPMENT 399
19.11 BIOHIT OYJ 400
19.11.1 COMPANY SNAPSHOT 400
19.11.2 REVENUE ANALYSIS 400
19.11.3 PRODUCT PORTFOLIO 401
19.11.4 RECENT DEVELOPMENT 401
19.12 DIASORIN S.P.A 402
19.12.1 COMPANY SNAPSHOT 402
19.12.2 REVENUE ANALYSIS 402
19.12.3 PRODUCT PORTFOLIO 403
19.12.4 RECENT DEVELOPMENT 403
19.13 ENDOFOTONICS PTE LTD 404
19.13.1 COMPANY SNAPSHOT 404
19.13.2 PRODUCT PORTFOLIO 404
19.13.3 RECENT DEVELOPMENT 404
19.14 FOUNDATION MEDICINE, INC. 405
19.14.1 COMPANY SNAPSHOT 405
19.14.2 PRODUCT PORTFOLIO 405
19.14.3 RECENT DEVELOPMENTS 405
19.15 FUJIREBIO (AN H.U. GROUP COMPANY) 406
19.15.1 COMPANY SNAPSHOT 406
19.15.2 REVENUE ANALYSIS 406
19.15.3 PRODUCT PORTFOLIO 407
19.15.4 RECENT DEVELOPMENT 407

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.